China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China

2020-09-02
|
ChinaMedical

On September 1, China Isotope & Radiation Corporation (CIRC) signed an exclusive distribution agreement with Bayer.


According to the agreement, Bayer will grant CIRC the exclusive right to sell Xofigo® (radium chloride [223Ra] injection) in China.


Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.


RELATED ARTICLES

Memoray completes tens of millions of yuan in Series B financing
2020-11-18
|
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

Orthopedic AI company Changmugu closes Series A+ of RMB tens of mlns
2020-09-12
|
PEVC , Medical care

Lu Daopei Medical closes Series B+ exceeding RMB 100 mln
2020-09-11
|
PEVC , Medical care

JD.com reaches strategic cooperation with Tongrentang Health
2020-09-09
|
Medical care , PEVC
China SDG